choline alphoscerate
PreclinicalSmall molecule
choline alphoscerate is one of 50 small molecule programs targeting Memory. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in Memory
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Ritalin
NovartisApproved
Myrbetriq
AstellasApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Ambien
PPurdue Pharma LP
Approved
Intuniv
PPromius Pharma, LLC
Approved
Mifeprex
DDanco
Approved
Nuvigil
NNuvo Research GmbH
Approved
Bendopa
MMerz North America, Inc.
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognitive impairment1 trial
Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment
Completed·—·Phase 2·NCT03228498·62 enrolled
Major Depression1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for choline alphoscerate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSamsung Medical Center